Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
2.120
+0.140 (7.07%)
At close: May 12, 2025, 4:00 PM
2.120
0.00 (0.01%)
After-hours: May 12, 2025, 7:58 PM EDT
MRVI Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for MRVI stock have an average target of 6.54, with a low estimate of 2.50 and a high estimate of 13. The average target predicts an increase of 208.49% from the current stock price of 2.12.
Analyst Consensus: Hold
* Price targets were last updated on Mar 25, 2025.
Analyst Ratings
The average analyst rating for MRVI stock from 9 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 1 | 2 | 2 | 1 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 4 | 4 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 11 | 11 | 9 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $5 | Hold | Maintains | $7 → $5 | +135.85% | Mar 25, 2025 |
| UBS | UBS | Hold Maintains $8 → $2.5 | Hold | Maintains | $8 → $2.5 | +17.92% | Mar 21, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $9 → $8 | Strong Buy | Maintains | $9 → $8 | +277.36% | Mar 3, 2025 |
| Baird | Baird | Buy → Hold Downgrades $9 → $3 | Buy → Hold | Downgrades | $9 → $3 | +41.51% | Feb 26, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Sell Downgrades $7 → $4.25 | Hold → Strong Sell | Downgrades | $7 → $4.25 | +100.47% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
196.60M
from 259.19M
Decreased by -24.15%
Revenue Next Year
218.51M
from 196.60M
Increased by 11.14%
EPS This Year
-0.26
from -1.05
EPS Next Year
-0.19
from -0.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 222.7M | 241.5M | 413.2M | ||
| Avg | 196.6M | 218.5M | 260.1M | ||
| Low | 181.3M | 197.0M | 210.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -14.1% | 22.8% | 89.1% | ||
| Avg | -24.1% | 11.1% | 19.0% | ||
| Low | -30.0% | 0.2% | -3.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.15 | -0.02 | 0.20 | ||
| Avg | -0.26 | -0.19 | -0.13 | ||
| Low | -0.41 | -0.40 | -0.39 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.